Research Advances in Targeting the YAP/TAZ Signaling Pathway
to Improve Cancer Immunotherapy.
10.3779/j.issn.1009-3419.2025.102.08
- Author:
Pingxu ZHANG
1
;
Yiyi ZHAN
1
Author Information
1. Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830000, China.
- Publication Type:English Abstract
- Keywords:
Immune evasion;
Immunotherapy;
TAZ;
Tumor microenvironment;
YAP
- MeSH:
Humans;
Immunotherapy/methods*;
Neoplasms/metabolism*;
Signal Transduction/drug effects*;
Adaptor Proteins, Signal Transducing/immunology*;
Animals;
Transcriptional Coactivator with PDZ-Binding Motif Proteins;
Transcription Factors/immunology*;
YAP-Signaling Proteins;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2025;28(3):221-229
- CountryChina
- Language:Chinese
-
Abstract:
Despite the groundbreaking advances in cancer immunotherapy achieved by immune checkpoint inhibitors (ICIs), their efficacy remains limited by the immunosuppressive tumor microenvironment (TME). Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), key effectors of the Hippo signaling pathway, play pivotal roles in tumor immune evasion. They directly regulate the expression of immune checkpoints, mediate the formation of an immunosuppressive microenvironment, inhibit T cell function, and interact with other signaling pathways to promote immune escape. Diverse strategies targeting YAP/TAZ have been developed, including direct inhibition, modulation of upstream regulators, and suppression of downstream target genes. Preclinical studies have demonstrated that combining YAP/TAZ inhibition with ICIs significantly enhances therapeutic efficacy across various tumor models. This review summarizes recent advances in understanding the role of YAP/TAZ in immune evasion within the TME and explores the potential of targeting this pathway to improve immunotherapy outcomes. Furthermore, it discusses the translational value of combination therapies based on YAP/TAZ inhibition, providing a theoretical framework and practical guidance for the development of innovative immunotherapeutic strategies and precision medicine approaches.
.
